What does AKV PHARMA do?

AKV PHARMA is a pharmacy in Pittem. Private Limited, started on 17 December 2015, 1 establishment.

What is the address of AKV PHARMA?

The registered office of AKV PHARMA is located at Koolskampstraat 69, 8740 Pittem.

Is AKV PHARMA still active?

Yes. According to the CBE (29 October 2026) AKV PHARMA is active, legal situation “Normale toestand”, started on 17 December 2015.

Is AKV PHARMA registered on Peppol?

Yes, AKV PHARMA is registered on the Peppol network with ID 0208:0644617062.

What is the enterprise number of AKV PHARMA?

The enterprise number of AKV PHARMA is BE0644617062.

When was AKV PHARMA founded?

AKV PHARMA was founded on 17 December 2015.

Who are the directors of AKV PHARMA?

According to the 2025 annual accounts, the directors of AKV PHARMA are: HM Pharma BV.

Is AKV PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 17 December 2015; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did AKV PHARMA make in 2025?

AKV PHARMA posted a profit after taxes of € 25,201 in financial year 2025.

What is the revenue of AKV PHARMA?

As a small company, AKV PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 40,416.

AKV PHARMA (Private Limited) - Pittem - BE0644617062

Dossier AKV PHARMA, printed on 29 October 2026 from databakkes.be/en/0644617062/akv-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

AKV PHARMA from Pittem, company number BE0644617062, closed financial year 2025 with a result of € 25,201 after tax. For that financial year AKV PHARMA recorded a gross margin of € 40,416 and equity of € 52,420. Compared with financial year 2024, the result moved from € 8,515 to € 25,201. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 23, 2026.

What it is worth Growing

€ 52,420

▲ 93% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 25,201

▲ 196% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 57,661

▲ 41% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 41,727.

Debts at end 2025

Bank debt

€ 4,602

▼ 86% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 32

▼ 87% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 1,436

▼ 16% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 34,487 Gross margin 2022: € 34,487 First fiscal year in the series	€ 35,134 Gross margin 2023: € 35,134 ▲ 2% vs 2022 (€ 34,487) Favourable step	€ 35,082 Gross margin 2024: € 35,082 Unchanged (€ 35,134) Unfavourable step	€ 40,416 Gross margin 2025: € 40,416 ▲ 15% vs 2024 (€ 35,082) Favourable step	▲ 15%
Profit after taxes	€ 8,549 Profit after taxes 2022: € 8,549 First fiscal year in the series	€ 7,280 Profit after taxes 2023: € 7,280 ▼ 15% vs 2022 (€ 8,549) Unfavourable step	€ 8,515 Profit after taxes 2024: € 8,515 ▲ 17% vs 2023 (€ 7,280) Favourable step	€ 25,201 Profit after taxes 2025: € 25,201 ▲ 196% vs 2024 (€ 8,515) Favourable step	▲ 196%
Equity	€ 63,605 Equity 2022: € 63,605 First fiscal year in the series	€ 70,884 Equity 2023: € 70,884 ▲ 11% vs 2022 (€ 63,605) Favourable step	€ 27,219 Equity 2024: € 27,219 ▼ 62% vs 2023 (€ 70,884) Unfavourable step	€ 52,420 Equity 2025: € 52,420 ▲ 93% vs 2024 (€ 27,219) Favourable step	▲ 93%
Total debts	€ 131,234 Total debts 2022: € 131,234 First fiscal year in the series	€ 104,750 Total debts 2023: € 104,750 ▼ 20% vs 2022 (€ 131,234) Favourable step	€ 117,618 Total debts 2024: € 117,618 ▲ 12% vs 2023 (€ 104,750) Unfavourable step	€ 6,144 Total debts 2025: € 6,144 ▼ 95% vs 2024 (€ 117,618) Favourable step	▼ 95%
Cash	€ 106,954 Cash 2022: € 106,954 First fiscal year in the series	€ 48,678 Cash 2023: € 48,678 ▼ 54% vs 2022 (€ 106,954) Unfavourable step	€ 40,795 Cash 2024: € 40,795 ▼ 16% vs 2023 (€ 48,678) Unfavourable step	€ 57,661 Cash 2025: € 57,661 ▲ 41% vs 2024 (€ 40,795) Favourable step	▲ 41%
Retained profit	€ 45,055 Retained profit 2022: € 45,055 First fiscal year in the series	€ 52,334 Retained profit 2023: € 52,334 ▲ 16% vs 2022 (€ 45,055) Favourable step	€ 16,526 Retained profit 2024: € 16,526 ▼ 68% vs 2023 (€ 52,334) Unfavourable step	€ 41,727 Retained profit 2025: € 41,727 ▲ 152% vs 2024 (€ 16,526) Favourable step	▲ 152%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 44,323 Dividend 2024: € 44,323 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 44,323) Unchanged	▼ 100%
Bank debt	€ 85,490 Bank debt 2022: € 85,490 First fiscal year in the series	€ 58,930 Bank debt 2023: € 58,930 ▼ 31% vs 2022 (€ 85,490) Favourable step	€ 31,969 Bank debt 2024: € 31,969 ▼ 46% vs 2023 (€ 58,930) Favourable step	€ 4,602 Bank debt 2025: € 4,602 ▼ 86% vs 2024 (€ 31,969) Favourable step	▼ 86%
Balance sheet total	€ 194,838 Balance sheet total 2022: € 194,838 First fiscal year in the series	€ 175,634 Balance sheet total 2023: € 175,634 ▼ 10% vs 2022 (€ 194,838) Unchanged	€ 144,837 Balance sheet total 2024: € 144,837 ▼ 18% vs 2023 (€ 175,634) Unchanged	€ 58,563 Balance sheet total 2025: € 58,563 ▼ 60% vs 2024 (€ 144,837) Unchanged	▼ 60%

Key figures of AKV PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to AKV PHARMA?

What happened at AKV PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 23, 2026 New annual accounts for financial year 2025: profit of € 25,201 (▲ 196% vs 2024). Source: NBB ↗
2026 HM Pharma BV became a director. NBB
Dec 17, 2015 New establishment in Oudenburg. KBO
Dec 17, 2015 Start of the company according to the CBE. KBO

In short

From € 8,549 profit in 2022 to € 25,201 profit in 2025.

Paid € 22,360 in corporate taxes since 2022.

Best year ever: 2025, with € 25,201 profit.

Paid out € 44,323 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

HM Pharma 100%

The stake of HM Pharma comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

AKV PHARMA

Behind AKV PHARMA is HM Pharma BV. The shares are held by HM Pharma (100%).

Directors

According to the 2025 annual accounts

HM Pharma BV

Bestuurder · represented by Hanne Martens

since 2026

Shareholders

HM Pharma

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Koolskampstraat 69

8740 Pittem

2.249.127.122

Marktstraat 32-34

8460 Oudenburg

Active since 17 December 2015

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

HM Pharma same network

€ 192,466 gross margin · 2026

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0644.617.062
VAT number: BE 0644.617.062
Registered office: Koolskampstraat 69, 8740 Pittem
Names & denominations: AKV PHARMA
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 17 December 2015
Peppol: Active · Active since 13 Jul 2026
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗